Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.

@article{Rivkin1989AdjuvantCV,
  title={Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.},
  author={Saul Eugene Rivkin and Stephanie Green and Barbara Metch and Harold Glucksberg and Nazil Gad-el-Mawla and John J. Constanzi and Barth Hoogstraten and John W. Athens and Terry M. Maloney and Charles Osborne},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1989},
  volume={7 9},
  pages={
          1229-38
        }
}
Four hundred forty-one women with operable breast cancer with histologically positive axillary nodes were randomized to receive either combination cyclophosphamide (60 mg/m2 orally everyday for 1 year); fluorouracil (300 mg/m2 intravenously [IV] weekly for 1 year); methotrexate (15 mg/m2 IV weekly for 1 year); vincristine (0.625 mg/m2 IV for 10 weeks); prednisone (30 mg/m2 orally days 1 to 14, 20 mg/m2 days 15 to 28, 10 mg/m2 days 29 to 42) (CMFVP) or single-agent melphalan (L-PAM) (5 mg/m2… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Similar Papers

Loading similar papers…